Venture Partner
Adam is a Venture Partner at Frazier Life Sciences, where he is focused on company creation opportunities. In addition, Adam currently serves as the Executive Board Chair at Callio Therapeutics, a company developing multi-payload antibody-drug conjugates.
Prior to Frazier, he served as co-founder, Chief Executive Officer and Board member at Icosavax (Nasdaq: ICVX), a company leveraging its virus-like particle platform to develop vaccines for respiratory diseases. He built a team that brought multiple product candidates into the clinic, including Icosavax’s RSV/hMPV combination vaccine, and led the company through its IPO and subsequent acquisition by AstraZeneca. Prior to Icosavax, Adam served as the Chief Executive Officer and Board member at PvP Biologics, a company developing an oral enzyme to treat celiac disease. Adam led the company from founding through its acquisition by Takeda. Previously, Adam served as co-founder and Chief Business Officer of Meritage Pharma from inception until its sale to Shire, leading to the first FDA-approved oral product to treat eosinophilic esophagitis (Eohilia).